Ace Therapeutics is a global leading provider of IBD research services. Our services include the advancement of basic IBD research, experimental modeling, and preclinical drug studies. Our services and expertise enable clients to develop effective therapies for IBD based on consistent and high-quality data.
With a wealth of experience in taking novel therapeutic agents from early-stage in vitro testing to candidate nomination, Ace Therapeutics' technical team is well-equipped to assist and advise on appropriate models and custom protocols in accordance with study objectives.
We accelerate decision-making milestones in IBD drug development, supporting our clients to delve deeper into disease mechanisms and translate these discoveries into novel solutions.
We apply decades of early-stage drug development experience and a fully customized approach to hone in on the specialized therapy for IBD.
Ace Therapeutics provides comprehensive IBD drug development services, including drug discovery, pharmaceutical research, and preclinical research, for pharmaceutical companies and research institutions. Our drug integrated services platform helps customers accelerate the process of new drug R&D with powerful project management and more efficient R&D services.
Through multi-omic analysis, studies of environmental changes, molecular analyses of the gut microbiota, and comprehensive analyses of the interactions between the innate and adaptive immune responses, Ace Therapeutics helps clients investigate the molecular changes and cellular responses associated with IBD pathology, and identify potential therapeutic targets.
Our exploratory biomarker discovery services are an effective tool that can help identify new biomarkers capable of monitoring disease progression, predicting treatment response, and assessing toxicity. Incorporating biomarkers discovery into your IBD drug development can accelerate the process of developing novel therapies.
Ace Therapeutics provides in vitro models of intestinal inflammation to help clients study IBD pathogenesis, discover new therapeutic targets, and screen novel drugs. We can use different types of cells to assess the effects of compounds in the treatment of IBD.
Ace Therapeutics recognizes the importance of using reliable and accurate animal models to advance your understanding of IBD and develop novel therapies. These models allow us help clients evaluate novel drugs and therapies and provide valuable insight into disease mechanisms and potential treatment options.
By delivering advanced intellectual insights and fostering close collaboration across disciplines, Ace Therapeutics harnesses its extensive capabilities to develop tailored solutions that accelerate IBD drug discovery programs. With our deep expertise and specialization in IBD, you can trust that your project is in capable hands.
Equipped to perform flexible colonoscopy assessments and magnetic resonance imaging (MRI) when required.
Our team of experts has developed a broad understanding of the inflammatory and immune mechanisms and pathways that underpin IBD pathology.
IBD drug discovery services can be offered as part of an integrated preclinical project package or as a stand-alone analytical option. Flexible approach with easy access to our global network of specialized laboratories.
Our team of skilled medicinal chemists and DMPK specialists offers a comprehensive drug discovery platform for IBD. We employ a diverse array of assays to examine crucial functions of inflammatory and immune cells, as well as microbes, enabling us to help clients develop groundbreaking therapies.
